London, UK – ValiRx Plc (AIM: VAL), a life science company focusing on early-stage cancer therapeutics and women’s health, is pleased to announce today the signature of a lease for
ValiRx PLC (AIM:VAL) Launch of Broker Offer to raise a maximum of £500,000
Launch of Broker Offer to raise a maximum of £500,000
ValiRx PLC (AIM:VAL) Quarterly Operational and Strategy Update
London, UK – ValiRx Plc (AIM: VAL), a life science company focusing on early-stage cancer therapeutics and women’s health, today provides an update on operational activities and strategy.
Poolbeg Pharma PLC (AIM:POLB) POLB 001 US Patent update
Continued expansion of IP portfolio enhancing protection of Poolbeg’s growing pipeline
ValiRx PLC (AIM:VAL) Live Shareholder Q&A and industry events
Live Q&A: London, UK – ValiRx Plc (AIM: VAL), a life science company focusing on early-stage cancer therapeutics and women’s health, invites shareholders to join the CEO, Suzy Dilly and
ValiRx PLC (AIM:VAL) Successful evaluation of breast cancer programme
London, UK – ValiRx Plc (AIM: VAL), a life science company focusing on early-stage cancer therapeutics and women’s health, is pleased to announce that the project subject to the Evaluation
Genflow Biosciences (LON:GENF) Research Agreement Signed with Magnitude Biosciences Limited
Genflow (LSE: GENF) is pleased to announce it has entered into a research agreement with Magnitude Biosciences Limited (“Magnitude”), a UK-based, specialist biotechnology research organisation that supports drug discovery and
ValiRx PLC (AIM:VAL) Update on VAL201 sub-license agreement
London, UK – ValiRx Plc (AIM: VAL), a life science company focusing on early-stage cancer therapeutics and women’s health, is today providing an update on its proposed sub-license agreement with
Genflow Biosciences (LON:GENF) International patent application
Patent portfolio strengthened with international patent application under the Patent Cooperation Treaty
ValiRx PLC (AIM:VAL) Update on proposed sub-license of VAL201
London, UK – ValiRx Plc (AIM: VAL), a life science company focusing on early-stage cancer therapeutics and women’s health today provides an update on progress towards the completion of the
ValiRx PLC (AIM:VAL) Operational and Strategy Update
London, UK – ValiRx Plc (AIM: VAL), a life science company focusing on early-stage cancer therapeutics and women’s health, today provides an update on operational activities and strategy.